<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">1755</journal-id><journal-id journal-id-type="pmc-domain">frontonco</journal-id><journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id><journal-title-group><journal-title>Frontiers in Oncology</journal-title></journal-title-group><issn pub-type="epub">2234-943X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11703891</article-id><article-id pub-id-type="pmcid-ver">PMC11703891.1</article-id><article-id pub-id-type="pmcaid">11703891</article-id><article-id pub-id-type="pmcaiid">11703891</article-id><article-id pub-id-type="pmid">39777347</article-id><article-id pub-id-type="doi">10.3389/fonc.2024.1506840</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Oncology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Superior 125-month outcome through cetuximab in the larynx organ preservation trial DeLOS-II: a single study center&#8217;s experience</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Wichmann</surname><given-names initials="G">Gunnar</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/536050"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name name-style="western"><surname>Wald</surname><given-names initials="T">Theresa</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2521282"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zebralla</surname><given-names initials="V">Veit</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/668696"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stoehr</surname><given-names initials="M">Matthaeus</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pirlich</surname><given-names initials="M">Markus</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wiegand</surname><given-names initials="S">Susanne</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/669662"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Kunz</surname><given-names initials="V">Viktor</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn004" ref-type="author-notes">
<sup>&#8225;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Dietz</surname><given-names initials="A">Andreas</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn004" ref-type="author-notes">
<sup>&#8225;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/304379"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Clinic for Otorhinolaryngology, University Hospital Leipzig</institution>, <addr-line>Leipzig</addr-line>, <country>Germany</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>The Comprehensive Cancer Center Central Germany, Leipzig University Hospital</institution>, <addr-line>Leipzig</addr-line>, <country>Germany</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>LIFE - Leipzig Research Center for Civilization Diseases, University of Leipzig</institution>, <addr-line>Leipzig</addr-line>, <country>Germany</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Schleswig-Holstein, Christian-Albrechts-University</institution>, <addr-line>Kiel</addr-line>, <country>Germany</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Panagiotis Balermpas, University Hospital Z&#252;rich, Switzerland</p></fn><fn fn-type="edited-by"><p>Reviewed by: Ali-Farid Safi, Craniologicum - Center for Craniomaxillofacial Surgery, Switzerland</p><p>Martin Leu, University Medical Center G&#246;ttingen, Germany</p><p>Vittoria Espeli, Oncology Institute of Southern Switzerland (IOSI), Switzerland</p></fn><corresp id="fn001">*Correspondence: Theresa Wald, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:theresa.wald@medizin.uni-leipzig.de">theresa.wald@medizin.uni-leipzig.de</email></corresp><fn fn-type="equal" id="fn003"><p>&#8224;These authors have contributed equally to this work and share first authorship</p></fn><fn fn-type="equal" id="fn004"><p>&#8225;These authors have contributed equally to this work and share senior authorship</p></fn></author-notes><pub-date pub-type="epub"><day>24</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">454181</issue-id><elocation-id>1506840</elocation-id><history><date date-type="received"><day>06</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>04</day><month>12</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>07</day><month>01</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-09 11:25:45.297"><day>09</day><month>01</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 Wichmann, Wald, Zebralla, Stoehr, Pirlich, Wiegand, Kunz and Dietz</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Wichmann, Wald, Zebralla, Stoehr, Pirlich, Wiegand, Kunz and Dietz</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fonc-14-1506840.pdf"/><abstract><sec><title>Introduction</title><p>The larynx organ preservation (LOP) trial DeLOS-II enrolled <italic toggle="yes">n</italic> = 173 patients with advanced laryngeal/hypopharyngeal squamous cell carcinoma (LHSCC) amenable (only curatively resectable) through total laryngectomy (TL) to receive induction chemotherapy (IC) with TPF [docetaxel (T), cisplatin (P), and 5-fluorouracil (F)] (arm A, 85 patients) or additional cetuximab (E) weekly (arm B, 88 patients). Responders with endoscopic estimated tumor surface shrinkage (ETSS) &#8805;30% after 1 cycle IC (IC-1) received a further two cycles of IC followed by radiotherapy (RT), whereas TL was recommended for non-responders. Arm B failed to show superior 24-month laryngectomy-free survival (LFS) and overall survival (OS), the protocol-specified primary and secondary endpoints. Ten years after the last per-protocol visit, we are interested in the long-term outcome of our clinic&#8217;s DeLOS-II patients.</p></sec><sec><title>Methods</title><p>Our cohort of 52 DeLOS-II patients accrued between 2007 and 2012 included 27 and 25 patients randomized to arms A and B, respectively. F was omitted because of severe toxicity with amendment 2 of the DeLOS-II protocol, leading to 21 and 31 patients receiving TPF and TP IC backbone, respectively. Follow-up data were collected using electronic health records and information from the German Centre for Cancer Registry Data to evaluate long-term LFS and OS in treatment groups.</p></sec><sec><title>Results</title><p>According to ETSS &#8805; 30%, 42 patients (80.8%; 21 and 21 corresponding to 77.8% and 84.0% in arms A and B, respectively) were responders to IC-1 and underwent the LOP attempt. Recommending early TL to non-responders (ETSS &lt; 30%), eight patients (five and three in A and B, respectively) underwent early TL. At 125 months, 22 (eight and 14) patients were alive: 17 (six and 11) with a functioning larynx and five (two and three) without a larynx. Arm B had superior OS (<italic toggle="yes">p</italic> = 0.023). Disease-specific survival (DSS) and tumor-specific survival were not different, whereas non-cancer-related survival (NCRS) was impaired in arm A (<italic toggle="yes">p</italic> = 0.018). Receiving TP or TPF IC did not significantly influence survival. Pairwise comparing OS of patients receiving TP, TPF, TPE, and TPFE revealed a benefit from cetuximab in TPE <italic toggle="yes">vs</italic>. TP (<italic toggle="yes">p</italic> = 0.020).</p></sec><sec><title>Conclusion</title><p>While the per-protocol DeLOS-II results earlier reported comparable 24-month LFS and OS in arms A and B, our subcohort&#8217;s long-term follow-up data demonstrate a superior 125-month outcome in arm B.</p></sec></abstract><kwd-group><kwd>head neck squamous cell carcinoma (HNSCC)</kwd><kwd>locoregional advanced head and neck cancer (LA HNC)</kwd><kwd>larynx cancer</kwd><kwd>hypopharynx cancer</kwd><kwd>larynx organ preservation</kwd><kwd>overall survival</kwd><kwd>neoadjuvant chemotherapy</kwd><kwd>cetuximab</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>Universit&#228;t Leipzig
</institution><institution-id institution-id-type="doi">10.13039/501100008678</institution-id></institution-wrap></funding-source></award-group><funding-statement>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Open Access Publishing Fund of Leipzig University.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="3"/><equation-count count="0"/><ref-count count="43"/><page-count count="12"/><word-count count="5652"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Head and Neck Cancer</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>The treatment of locally advanced (LA) laryngeal/hypopharyngeal squamous cell carcinoma (LHSCC) is challenging concerning survival and functional outcomes, including talking, swallowing, and breathing. Many tumors are solely completely (R0)&#8211;resectable via total laryngectomy (TL) and neck dissection (ND), potentially followed by adjuvant therapy [i.e., postoperative radiotherapy without (PORT) or with concomitant platinum-based chemotherapy (PORCT)]. Concurrent chemoradiation (CRT) with cisplatin (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>) and induction chemotherapy with PF (cisplatin and 5-fluorouracil) followed by radiotherapy (<xref rid="B3" ref-type="bibr">3</xref>) or TPF (docetaxel or another taxane combined with PF) followed by radiotherapy (<xref rid="B4" ref-type="bibr">4</xref>&#8211;<xref rid="B7" ref-type="bibr">7</xref>) are well-established alternatives to TL + ND + POR(C)T, at least for selected patients with rather small cT3 LHSCC and limited locoregional spread, preferably cN0 or cN1 (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>). Induction chemotherapy (IC) + RT and CRT offer the possibility of larynx organ preservation (LOP) by avoiding ablative surgery (<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B10" ref-type="bibr">10</xref>). Both IC + RT and CRT are accepted as alternative LOP approaches and are capable of preserving the larynx and its function in a substantial proportion of patients (<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B10" ref-type="bibr">10</xref>). In cT4a tumors, however, a surgical approach is recommended, as CRT was found to be associated with decreased survival and high rates of severe late toxicity (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>).</p><p>Several LOP trials explored IC in patients amenable to surgical treatment with TL (<xref rid="B3" ref-type="bibr">3</xref>&#8211;<xref rid="B7" ref-type="bibr">7</xref>). Inspired by the results of the Bonner trial that demonstrated a benefit from adding cetuximab (Erbitux<sup>&#174;</sup>, E) to radiotherapy (<xref rid="B13" ref-type="bibr">13</xref>), the German LOP trial DeLOS-II (<xref rid="B14" ref-type="bibr">14</xref>) investigated E added to IC + RT. The objective of DeLOS-II was to evaluate the effect of adding cetuximab (loading dose 400 mg/m<sup>2</sup> followed by 250 mg/m<sup>2</sup> weekly for up to 6 months) to IC with docetaxel (T; 75 mg/m<sup>2</sup> on day 1), cisplatin (P; 75 mg/m<sup>2</sup> on day 1), and 5-fluorouracil (5-FU; 750 mg/m<sup>2</sup> on days 1&#8211;5; later omitted from the protocol because of severe toxicity). In DeLOS-II, 173 patients were treated with one cycle IC followed by early response evaluation (ERE) using the newly established criterion of endoscopic estimated tumor surface shrinkage (ETSS) &#8805;30% to discriminate responders and patients with insufficient response (non-responders). Responders with ETSS &#8805; 30% additionally received two cycles of IC followed by radiotherapy (RT). Non-responders received the recommendation for TL + ND followed by adjuvant treatment according to the recommendation of the local multidisciplinary tumor board (MDTB). The primary endpoint was 24-month laryngectomy-free survival (LFS), and the secondary endpoints were 24-month overall survival (OS) and 6- and 24-month functional LFS (fLFS), early response after IC-1, toxicity, and complications during and after salvage surgery (<xref rid="B14" ref-type="bibr">14</xref>). The primary objective (24-month LFS significantly above 35%) was equally met by both treatment arms (with and without cetuximab). The 24-month OS did not differ significantly between arms (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). This, however, suggested the absence of significantly beneficial effects of additional cetuximab. Within an earlier subgroup analysis conducted after approximately 5 years of follow-up, we also reported slightly different outcomes between patients of arm A <italic toggle="yes">vs.</italic> arm B favoring (<xref rid="B15" ref-type="bibr">15</xref>). Now, 12 years after enrolling the last LA-LHSCC patient in DeLOS-II, we evaluated long-term follow-up data of the subgroup of <italic toggle="yes">n</italic> = 52 treated in our University Hospital and compared their outcomes with those achieved by each of the three alternative guideline-conform treatments, TL + ND + PORT, TL + ND + PORCT, and cisplatin-based CRT (<xref rid="B16" ref-type="bibr">16</xref>). We found DeLOS-II to be superior regarding the achieved outcome in general and could provide evidence for this superiority based on a comparison of propensity score (PS)-matched cases (<xref rid="B16" ref-type="bibr">16</xref>). Here, we provide additional data about the outcome differences among <italic toggle="yes">n</italic> = 52 DeLOS-II patients according to IC backbone, TPF <italic toggle="yes">vs.</italic> TP, the efficacy of cetuximab (arm B <italic toggle="yes">vs.</italic> arm A), and the different outcomes achieved by the four treatment regimens: TPF <italic toggle="yes">vs.</italic> TPFE <italic toggle="yes">vs.</italic> TP <italic toggle="yes">vs.</italic> TPE.</p></sec><sec id="s2"><title>Methods</title><p>Originally, 173 patients were treated according to the DeLOS-II protocol at 22 study centers with the University Hospital Leipzig recruiting 52 patients, the highest number per study center. Detailed information concerning the study protocol is published elsewhere (<xref rid="B14" ref-type="bibr">14</xref>).</p><p>In brief, the study protocol of DeLOS-II utilized the first cycle of IC (IC-1) consisting of docetaxel (75 mg/m<sup>2</sup>; T) and cisplatin (75 mg/m<sup>2</sup>; P) on day 1 and 5-fluorouracil (750 mg/m<sup>2</sup>; F) on days 1&#8211;5 for response evaluation. F was later omitted from the protocol because of severe toxicity. Three weeks after IC-1, an endoscopy under general anesthesia was performed aiming for an estimation of the ETSS. Patients achieving ETSS &#8805; 30% were considered responders and received a further two cycles of IC, whereas to poorly responding LHSCC patients with ETSS &lt; 30% or progressing disease, early TL was recommended. Patients randomized into arm B received the identical treatment but additionally E [400 mg/m<sup>2</sup> loading dose (day 1) followed by 250 mg/m<sup>2</sup> weekly over 16 weeks in total].</p><p>Long-term follow-up data of these 52 patients were collected using electronic health records and information provided by the German Centre for Cancer Registry Data to evaluate 10-year survival including OS, tumor-specific survival (TSS), non-cancer-related survival (NCRS), and LFS. For statistical analyses, SPSS (SPSS version 29, IBM Corporation, Armonk, NY, USA) was used. Univariate analyses of categorical data included Pearson&#8217;s chi-squared tests and Fisher&#8217;s exact test, while cardinal-metric data were compared using homo- or heteroscedastic Student&#8217;s <italic toggle="yes">t</italic>-tests. The Kaplan&#8211;Meier cumulative survival plots (<xref rid="B17" ref-type="bibr">17</xref>), log-rank tests (<xref rid="B18" ref-type="bibr">18</xref>), Cox proportional hazards regression (<xref rid="B19" ref-type="bibr">19</xref>) utilizing the conditional logistic regression forward method, and bootstrapping (<xref rid="B20" ref-type="bibr">20</xref>) were used to analyze time-to-event data, LFS, OS, disease-specific survival (DSS), TSS, and NCRS. All time-to-event data were calculated from the time of randomization to the event (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). Events were considered death from all causes (OS), death caused by head and neck squamous cell carcinoma (HNSCC) (DSS), death caused by any malignant tumor (HNSCC or cancer of other histology; TSS), or death caused by non-cancer-specific (other than cancer-related) reasons (NCRS), whereas patients alive or without the specified event were right-censored at time of last follow-up. Gaining more importance within the course of follow-up duration, NCRS was reported. Laryngectomy-free survival was calculated from the time of diagnosis to TL. Two-sided <italic toggle="yes">p</italic> &lt; 0.05 was considered significant.</p></sec><sec sec-type="results" id="s3"><title>Results</title><p>The characteristics of the 52 DeLOS-II patients treated at the University Hospital Leipzig are shown in <xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>, representing 30.1% of the whole study population with 173 patients (<xref rid="B14" ref-type="bibr">14</xref>). According to stratification factors in randomization (T4 <italic toggle="yes">vs.</italic> other, N0/N1 <italic toggle="yes">vs.</italic> N2/N3, and larynx <italic toggle="yes">vs.</italic> hypopharynx), arms A and B are not different regarding these covariates and IC backbone TPF <italic toggle="yes">vs.</italic> TP (all <italic toggle="yes">p</italic> &#8805; 0.404) and also with respect to age categories, sex, smoking, alcohol consumption, and comorbidities when applying the Charlson score (all <italic toggle="yes">p</italic> &#8805; 0.220).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Characteristics of the 52 DeLOS-II patients treated at the University Hospital Leipzig from 2007 to 2012 in arms A and B of the DeLOS-II trial.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" rowspan="3" colspan="2" align="left">Characteristics</th><th valign="middle" colspan="2" align="left" rowspan="1">DeLOS-II</th><th valign="middle" colspan="2" align="left" rowspan="1">Arm A</th><th valign="middle" colspan="2" align="left" rowspan="1">Arm B</th><th valign="middle" rowspan="3" align="right" colspan="1">
<italic toggle="yes">p</italic>-Value</th></tr><tr><th valign="middle" colspan="2" align="left" rowspan="1">(<italic toggle="yes">n</italic> = 52)</th><th valign="middle" colspan="2" align="left" rowspan="1">(<italic toggle="yes">n</italic> = 27)</th><th valign="middle" colspan="2" align="left" rowspan="1">(<italic toggle="yes">n</italic> = 25)</th></tr><tr><th valign="bottom" align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th valign="bottom" align="left" rowspan="1" colspan="1">(%)</th><th valign="bottom" align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th valign="bottom" align="left" rowspan="1" colspan="1">(%)</th><th valign="bottom" align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th valign="bottom" align="left" rowspan="1" colspan="1">(%)</th></tr></thead><tbody><tr><th valign="middle" colspan="9" align="left" rowspan="1">Age (years)</th></tr><tr><td valign="middle" colspan="2" align="right" rowspan="1">&lt;50</td><td valign="middle" align="right" rowspan="1" colspan="1">14</td><td valign="bottom" align="right" rowspan="1" colspan="1">(27)</td><td valign="middle" align="right" rowspan="1" colspan="1">6</td><td valign="bottom" align="right" rowspan="1" colspan="1">(22)</td><td valign="middle" align="right" rowspan="1" colspan="1">8</td><td valign="bottom" align="right" rowspan="1" colspan="1">(32)</td><td valign="bottom" align="right" rowspan="1" colspan="1">0.594</td></tr><tr><td valign="middle" colspan="2" align="right" rowspan="1">50&#8211;59</td><td valign="middle" align="right" rowspan="1" colspan="1">23</td><td valign="bottom" align="right" rowspan="1" colspan="1">(44)</td><td valign="middle" align="right" rowspan="1" colspan="1">14</td><td valign="bottom" align="right" rowspan="1" colspan="1">(52)</td><td valign="middle" align="right" rowspan="1" colspan="1">9</td><td valign="bottom" align="right" rowspan="1" colspan="1">(36)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><td valign="middle" colspan="2" align="right" rowspan="1">60&#8211;69</td><td valign="middle" align="right" rowspan="1" colspan="1">10</td><td valign="bottom" align="right" rowspan="1" colspan="1">(19)</td><td valign="middle" align="right" rowspan="1" colspan="1">4</td><td valign="bottom" align="right" rowspan="1" colspan="1">(15)</td><td valign="middle" align="right" rowspan="1" colspan="1">6</td><td valign="bottom" align="right" rowspan="1" colspan="1">(24)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><td valign="middle" colspan="2" align="right" rowspan="1">&#8805;70</td><td valign="middle" align="right" rowspan="1" colspan="1">5</td><td valign="bottom" align="right" rowspan="1" colspan="1">(10)</td><td valign="middle" align="right" rowspan="1" colspan="1">3</td><td valign="bottom" align="right" rowspan="1" colspan="1">(11)</td><td valign="middle" align="right" rowspan="1" colspan="1">2</td><td valign="bottom" align="right" rowspan="1" colspan="1">(8)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><th valign="middle" colspan="9" align="left" rowspan="1">Sex</th></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">Male</td><td valign="middle" align="right" rowspan="1" colspan="1">44</td><td valign="bottom" align="right" rowspan="1" colspan="1">(85)</td><td valign="middle" align="right" rowspan="1" colspan="1">22</td><td valign="bottom" align="right" rowspan="1" colspan="1">(81)</td><td valign="middle" align="right" rowspan="1" colspan="1">22</td><td valign="bottom" align="right" rowspan="1" colspan="1">(88)</td><td valign="bottom" align="right" rowspan="1" colspan="1">0.515</td></tr><tr><td valign="middle" colspan="2" align="right" rowspan="1">Female</td><td valign="middle" align="right" rowspan="1" colspan="1">8</td><td valign="bottom" align="right" rowspan="1" colspan="1">(15)</td><td valign="middle" align="right" rowspan="1" colspan="1">5</td><td valign="bottom" align="right" rowspan="1" colspan="1">(19)</td><td valign="middle" align="right" rowspan="1" colspan="1">3</td><td valign="bottom" align="right" rowspan="1" colspan="1">(12)</td><td valign="bottom" align="right" rowspan="1" colspan="1"/></tr><tr><th valign="middle" colspan="9" align="left" rowspan="1">Tobacco smoking</th></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">0 pack years</td><td valign="middle" align="right" rowspan="1" colspan="1">0</td><td valign="bottom" align="right" rowspan="1" colspan="1">(0)</td><td valign="middle" align="right" rowspan="1" colspan="1">0</td><td valign="bottom" align="right" rowspan="1" colspan="1">(0)</td><td valign="middle" align="right" rowspan="1" colspan="1">0</td><td valign="bottom" align="right" rowspan="1" colspan="1">(0)</td><td valign="bottom" align="right" rowspan="1" colspan="1">0.999</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">&#8804;30 pack years</td><td valign="middle" align="right" rowspan="1" colspan="1">25</td><td valign="bottom" align="right" rowspan="1" colspan="1">(48)</td><td valign="middle" align="right" rowspan="1" colspan="1">13</td><td valign="bottom" align="right" rowspan="1" colspan="1">(48)</td><td valign="middle" align="right" rowspan="1" colspan="1">12</td><td valign="bottom" align="right" rowspan="1" colspan="1">(48)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">&gt;30 pack years</td><td valign="middle" align="right" rowspan="1" colspan="1">27</td><td valign="bottom" align="right" rowspan="1" colspan="1">(52)</td><td valign="middle" align="right" rowspan="1" colspan="1">14</td><td valign="bottom" align="right" rowspan="1" colspan="1">(52)</td><td valign="middle" align="right" rowspan="1" colspan="1">13</td><td valign="bottom" align="right" rowspan="1" colspan="1">(52)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">Never</td><td valign="middle" align="right" rowspan="1" colspan="1">0</td><td valign="bottom" align="right" rowspan="1" colspan="1">(0)</td><td valign="middle" align="right" rowspan="1" colspan="1">0</td><td valign="bottom" align="right" rowspan="1" colspan="1">(0)</td><td valign="middle" align="right" rowspan="1" colspan="1">0</td><td valign="bottom" align="right" rowspan="1" colspan="1">(0)</td><td valign="bottom" align="right" rowspan="1" colspan="1">0.220</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">Former</td><td valign="middle" align="right" rowspan="1" colspan="1">9</td><td valign="bottom" align="right" rowspan="1" colspan="1">(17)</td><td valign="middle" align="right" rowspan="1" colspan="1">3</td><td valign="bottom" align="right" rowspan="1" colspan="1">(11)</td><td valign="middle" align="right" rowspan="1" colspan="1">6</td><td valign="bottom" align="right" rowspan="1" colspan="1">(24)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">Current</td><td valign="middle" align="right" rowspan="1" colspan="1">43</td><td valign="bottom" align="right" rowspan="1" colspan="1">(83)</td><td valign="middle" align="right" rowspan="1" colspan="1">24</td><td valign="bottom" align="right" rowspan="1" colspan="1">(89)</td><td valign="middle" align="right" rowspan="1" colspan="1">19</td><td valign="bottom" align="right" rowspan="1" colspan="1">(76)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><th valign="middle" colspan="9" align="left" rowspan="1">Alcohol consumption</th></tr><tr><td valign="bottom" align="right" rowspan="1" colspan="1">0</td><td valign="bottom" align="center" rowspan="1" colspan="1">g/d</td><td valign="middle" align="right" rowspan="1" colspan="1">2</td><td valign="bottom" align="right" rowspan="1" colspan="1">(4)</td><td valign="middle" align="right" rowspan="1" colspan="1">1</td><td valign="bottom" align="right" rowspan="1" colspan="1">(4)</td><td valign="middle" align="right" rowspan="1" colspan="1">1</td><td valign="bottom" align="right" rowspan="1" colspan="1">(4)</td><td valign="bottom" align="right" rowspan="1" colspan="1">0.560</td></tr><tr><td valign="bottom" align="right" rowspan="1" colspan="1">1&#8211;30</td><td valign="bottom" align="center" rowspan="1" colspan="1">g/d</td><td valign="middle" align="right" rowspan="1" colspan="1">18</td><td valign="bottom" align="right" rowspan="1" colspan="1">(35)</td><td valign="middle" align="right" rowspan="1" colspan="1">7</td><td valign="bottom" align="right" rowspan="1" colspan="1">(26)</td><td valign="middle" align="right" rowspan="1" colspan="1">11</td><td valign="bottom" align="right" rowspan="1" colspan="1">(44)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><td valign="bottom" align="right" rowspan="1" colspan="1">31&#8211;60</td><td valign="bottom" align="center" rowspan="1" colspan="1">g/d</td><td valign="middle" align="right" rowspan="1" colspan="1">11</td><td valign="bottom" align="right" rowspan="1" colspan="1">(21)</td><td valign="middle" align="right" rowspan="1" colspan="1">7</td><td valign="bottom" align="right" rowspan="1" colspan="1">(26)</td><td valign="middle" align="right" rowspan="1" colspan="1">4</td><td valign="bottom" align="right" rowspan="1" colspan="1">(16)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><td valign="bottom" align="right" rowspan="1" colspan="1">&gt;60</td><td valign="bottom" align="center" rowspan="1" colspan="1">g/d</td><td valign="middle" align="right" rowspan="1" colspan="1">21</td><td valign="bottom" align="right" rowspan="1" colspan="1">(40)</td><td valign="middle" align="right" rowspan="1" colspan="1">12</td><td valign="bottom" align="right" rowspan="1" colspan="1">(44)</td><td valign="middle" align="right" rowspan="1" colspan="1">9</td><td valign="bottom" align="right" rowspan="1" colspan="1">(36)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><th valign="middle" colspan="9" align="left" rowspan="1">Tumor location, stage</th></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">Hypopharynx</td><td valign="middle" align="right" rowspan="1" colspan="1">30</td><td valign="bottom" align="right" rowspan="1" colspan="1">(58)</td><td valign="middle" align="right" rowspan="1" colspan="1">15</td><td valign="bottom" align="right" rowspan="1" colspan="1">(56)</td><td valign="middle" align="right" rowspan="1" colspan="1">15</td><td valign="bottom" align="right" rowspan="1" colspan="1">(60)</td><td valign="bottom" align="right" rowspan="1" colspan="1">0.764</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">Larynx</td><td valign="bottom" align="right" rowspan="1" colspan="1">22</td><td valign="bottom" align="right" rowspan="1" colspan="1">(42)</td><td valign="bottom" align="right" rowspan="1" colspan="1">12</td><td valign="bottom" align="right" rowspan="1" colspan="1">(44)</td><td valign="bottom" align="right" rowspan="1" colspan="1">10</td><td valign="bottom" align="right" rowspan="1" colspan="1">(40)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">T2</td><td valign="bottom" align="right" rowspan="1" colspan="1">6</td><td valign="bottom" align="right" rowspan="1" colspan="1">(12)</td><td valign="bottom" align="right" rowspan="1" colspan="1">3</td><td valign="bottom" align="right" rowspan="1" colspan="1">(11)</td><td valign="bottom" align="right" rowspan="1" colspan="1">3</td><td valign="bottom" align="right" rowspan="1" colspan="1">(12)</td><td valign="bottom" align="right" rowspan="1" colspan="1">0.516</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">T3</td><td valign="middle" align="right" rowspan="1" colspan="1">27</td><td valign="bottom" align="right" rowspan="1" colspan="1">(52)</td><td valign="middle" align="right" rowspan="1" colspan="1">16</td><td valign="bottom" align="right" rowspan="1" colspan="1">(59)</td><td valign="middle" align="right" rowspan="1" colspan="1">11</td><td valign="bottom" align="right" rowspan="1" colspan="1">(44)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">T4a</td><td valign="middle" align="right" rowspan="1" colspan="1">19</td><td valign="bottom" align="right" rowspan="1" colspan="1">(37)</td><td valign="middle" align="right" rowspan="1" colspan="1">8</td><td valign="bottom" align="right" rowspan="1" colspan="1">(30)</td><td valign="middle" align="right" rowspan="1" colspan="1">11</td><td valign="bottom" align="right" rowspan="1" colspan="1">(44)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">N0</td><td valign="bottom" align="right" rowspan="1" colspan="1">9</td><td valign="bottom" align="right" rowspan="1" colspan="1">(17)</td><td valign="bottom" align="right" rowspan="1" colspan="1">6</td><td valign="bottom" align="right" rowspan="1" colspan="1">(22)</td><td valign="bottom" align="right" rowspan="1" colspan="1">3</td><td valign="bottom" align="right" rowspan="1" colspan="1">(12)</td><td valign="bottom" align="right" rowspan="1" colspan="1">0.404</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">N1</td><td valign="middle" align="right" rowspan="1" colspan="1">4</td><td valign="bottom" align="right" rowspan="1" colspan="1">(8)</td><td valign="middle" align="right" rowspan="1" colspan="1">3</td><td valign="bottom" align="right" rowspan="1" colspan="1">(11)</td><td valign="middle" align="right" rowspan="1" colspan="1">1</td><td valign="bottom" align="right" rowspan="1" colspan="1">(4)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">N2a</td><td valign="middle" align="right" rowspan="1" colspan="1">0</td><td valign="bottom" align="right" rowspan="1" colspan="1">(0)</td><td valign="middle" align="right" rowspan="1" colspan="1">0</td><td valign="bottom" align="right" rowspan="1" colspan="1">(0)</td><td valign="middle" align="right" rowspan="1" colspan="1">0</td><td valign="bottom" align="right" rowspan="1" colspan="1">(0)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">N2b</td><td valign="middle" align="right" rowspan="1" colspan="1">20</td><td valign="bottom" align="right" rowspan="1" colspan="1">(38)</td><td valign="middle" align="right" rowspan="1" colspan="1">11</td><td valign="bottom" align="right" rowspan="1" colspan="1">(41)</td><td valign="middle" align="right" rowspan="1" colspan="1">9</td><td valign="bottom" align="right" rowspan="1" colspan="1">(36)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">N2c</td><td valign="middle" align="right" rowspan="1" colspan="1">18</td><td valign="bottom" align="right" rowspan="1" colspan="1">(35)</td><td valign="middle" align="right" rowspan="1" colspan="1">7</td><td valign="bottom" align="right" rowspan="1" colspan="1">(26)</td><td valign="middle" align="right" rowspan="1" colspan="1">11</td><td valign="bottom" align="right" rowspan="1" colspan="1">(44)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">N3</td><td valign="middle" align="right" rowspan="1" colspan="1">1</td><td valign="bottom" align="right" rowspan="1" colspan="1">(2)</td><td valign="middle" align="right" rowspan="1" colspan="1">0</td><td valign="bottom" align="right" rowspan="1" colspan="1">(0)</td><td valign="middle" align="right" rowspan="1" colspan="1">1</td><td valign="bottom" align="right" rowspan="1" colspan="1">(4)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">Stage II (UICC)</td><td valign="bottom" align="right" rowspan="1" colspan="1">1</td><td valign="bottom" align="right" rowspan="1" colspan="1">(2)</td><td valign="bottom" align="right" rowspan="1" colspan="1">1</td><td valign="bottom" align="right" rowspan="1" colspan="1">(4)</td><td valign="bottom" align="right" rowspan="1" colspan="1">0</td><td valign="bottom" align="right" rowspan="1" colspan="1">(0)</td><td valign="bottom" align="right" rowspan="1" colspan="1">0.338</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">Stage III (UICC)</td><td valign="middle" align="right" rowspan="1" colspan="1">12</td><td valign="bottom" align="right" rowspan="1" colspan="1">(23)</td><td valign="middle" align="right" rowspan="1" colspan="1">8</td><td valign="bottom" align="right" rowspan="1" colspan="1">(29)</td><td valign="middle" align="right" rowspan="1" colspan="1">4</td><td valign="bottom" align="right" rowspan="1" colspan="1">(16)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">Stage IVA (UICC)</td><td valign="middle" align="right" rowspan="1" colspan="1">38</td><td valign="bottom" align="right" rowspan="1" colspan="1">(73)</td><td valign="middle" align="right" rowspan="1" colspan="1">18</td><td valign="bottom" align="right" rowspan="1" colspan="1">(67)</td><td valign="middle" align="right" rowspan="1" colspan="1">20</td><td valign="bottom" align="right" rowspan="1" colspan="1">(80)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">Stage IVB (UICC)</td><td valign="middle" align="right" rowspan="1" colspan="1">1</td><td valign="bottom" align="right" rowspan="1" colspan="1">(2)</td><td valign="middle" align="right" rowspan="1" colspan="1">0</td><td valign="bottom" align="right" rowspan="1" colspan="1">(0)</td><td valign="middle" align="right" rowspan="1" colspan="1">1</td><td valign="bottom" align="right" rowspan="1" colspan="1">(4)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><th valign="middle" colspan="9" align="left" rowspan="1">Induction chemotherapy</th></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">TP</td><td valign="middle" align="right" rowspan="1" colspan="1">31</td><td valign="bottom" align="right" rowspan="1" colspan="1">(60)</td><td valign="middle" align="right" rowspan="1" colspan="1">16</td><td valign="bottom" align="right" rowspan="1" colspan="1">(59)</td><td valign="middle" align="right" rowspan="1" colspan="1">15</td><td valign="bottom" align="right" rowspan="1" colspan="1">(60)</td><td valign="bottom" align="right" rowspan="1" colspan="1">0.999</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">TPF</td><td valign="middle" align="right" rowspan="1" colspan="1">21</td><td valign="bottom" align="right" rowspan="1" colspan="1">(40)</td><td valign="bottom" align="right" rowspan="1" colspan="1">11</td><td valign="bottom" align="right" rowspan="1" colspan="1">(41)</td><td valign="bottom" align="right" rowspan="1" colspan="1">10</td><td valign="bottom" align="right" rowspan="1" colspan="1">(40)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><th valign="bottom" colspan="9" align="left" rowspan="1">ERE after IC-1</th></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">IC-related death</td><td valign="middle" align="right" rowspan="1" colspan="1">2</td><td valign="middle" align="right" rowspan="1" colspan="1">(4)</td><td valign="middle" align="right" rowspan="1" colspan="1">2</td><td valign="middle" align="right" rowspan="1" colspan="1">(7)</td><td valign="middle" align="right" rowspan="1" colspan="1">0</td><td valign="middle" align="right" rowspan="1" colspan="1">&#8211;</td><td valign="middle" align="right" rowspan="1" colspan="1">0.340</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">Non-responder (ETSS &lt; 30%)</td><td valign="middle" align="right" rowspan="1" colspan="1">10</td><td valign="middle" align="right" rowspan="1" colspan="1">(19)</td><td valign="middle" align="right" rowspan="1" colspan="1">6</td><td valign="middle" align="right" rowspan="1" colspan="1">(22)</td><td valign="middle" align="right" rowspan="1" colspan="1">4</td><td valign="middle" align="right" rowspan="1" colspan="1">(16)</td><td valign="middle" align="right" rowspan="1" colspan="1"/></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">Responder (ETSS &#8805; 30%)</td><td valign="middle" align="right" rowspan="1" colspan="1">39</td><td valign="middle" align="right" rowspan="1" colspan="1">(75)</td><td valign="middle" align="right" rowspan="1" colspan="1">19</td><td valign="middle" align="right" rowspan="1" colspan="1">(71)</td><td valign="middle" align="right" rowspan="1" colspan="1">20</td><td valign="middle" align="right" rowspan="1" colspan="1">(80)</td><td valign="middle" align="left" rowspan="1" colspan="1">
</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">N/A<xref rid="fnT1_1" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td valign="middle" align="right" rowspan="1" colspan="1">1</td><td valign="middle" align="right" rowspan="1" colspan="1">(2)</td><td valign="middle" align="right" rowspan="1" colspan="1">0</td><td valign="middle" align="right" rowspan="1" colspan="1">&#8211;</td><td valign="middle" align="right" rowspan="1" colspan="1">1</td><td valign="middle" align="right" rowspan="1" colspan="1">(4)</td><td valign="bottom" align="left" rowspan="1" colspan="1">
</td></tr><tr><th valign="middle" colspan="9" align="left" rowspan="1">Total laryngectomy</th></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">No TL</td><td valign="middle" align="right" rowspan="1" colspan="1">35</td><td valign="bottom" align="right" rowspan="1" colspan="1">(67)</td><td valign="middle" align="right" rowspan="1" colspan="1">18</td><td valign="bottom" align="right" rowspan="1" colspan="1">(67)</td><td valign="middle" align="right" rowspan="1" colspan="1">17</td><td valign="bottom" align="right" rowspan="1" colspan="1">(68)</td><td valign="bottom" align="right" rowspan="1" colspan="1">0.676</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">Early TL</td><td valign="middle" align="right" rowspan="1" colspan="1">8</td><td valign="bottom" align="right" rowspan="1" colspan="1">(15)</td><td valign="bottom" align="right" rowspan="1" colspan="1">5</td><td valign="bottom" align="right" rowspan="1" colspan="1">(19)</td><td valign="bottom" align="right" rowspan="1" colspan="1">3</td><td valign="bottom" align="right" rowspan="1" colspan="1">(12)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">Late TL</td><td valign="middle" align="right" rowspan="1" colspan="1">9</td><td valign="bottom" align="right" rowspan="1" colspan="1">(17)</td><td valign="bottom" align="right" rowspan="1" colspan="1">4</td><td valign="bottom" align="right" rowspan="1" colspan="1">(15)</td><td valign="bottom" align="right" rowspan="1" colspan="1">5</td><td valign="bottom" align="right" rowspan="1" colspan="1">(20)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><th valign="middle" colspan="9" align="left" rowspan="1">Radiotherapy</th></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">Yes</td><td valign="middle" align="right" rowspan="1" colspan="1">49</td><td valign="bottom" align="right" rowspan="1" colspan="1">(94)</td><td valign="bottom" align="right" rowspan="1" colspan="1">24</td><td valign="bottom" align="right" rowspan="1" colspan="1">(89)</td><td valign="bottom" align="right" rowspan="1" colspan="1">25</td><td valign="bottom" align="right" rowspan="1" colspan="1">(100)</td><td valign="bottom" align="right" rowspan="1" colspan="1">0.236</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">No</td><td valign="middle" align="right" rowspan="1" colspan="1">3</td><td valign="bottom" align="right" rowspan="1" colspan="1">(6)</td><td valign="bottom" align="right" rowspan="1" colspan="1">3</td><td valign="bottom" align="right" rowspan="1" colspan="1">(11)</td><td valign="bottom" align="right" rowspan="1" colspan="1">0</td><td valign="bottom" align="right" rowspan="1" colspan="1">(0)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr><tr><th valign="middle" colspan="9" align="left" rowspan="1">Charlson score</th></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">CS = 0</td><td valign="middle" align="right" rowspan="1" colspan="1">34</td><td valign="bottom" align="right" rowspan="1" colspan="1">(65)</td><td valign="middle" align="right" rowspan="1" colspan="1">18</td><td valign="bottom" align="right" rowspan="1" colspan="1">(67)</td><td valign="middle" align="right" rowspan="1" colspan="1">16</td><td valign="bottom" align="right" rowspan="1" colspan="1">(64)</td><td valign="bottom" align="right" rowspan="1" colspan="1">0.999</td></tr><tr><td valign="bottom" colspan="2" align="right" rowspan="1">CS &gt; 0</td><td valign="middle" align="right" rowspan="1" colspan="1">18</td><td valign="bottom" align="right" rowspan="1" colspan="1">(35)</td><td valign="bottom" align="right" rowspan="1" colspan="1">9</td><td valign="bottom" align="right" rowspan="1" colspan="1">(33)</td><td valign="bottom" align="right" rowspan="1" colspan="1">9</td><td valign="bottom" align="right" rowspan="1" colspan="1">(36)</td><td valign="bottom" align="right" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>
<italic toggle="yes">p</italic>-Values were calculated using Fisher&#8217;s exact test and Pearson&#8217;s chi-squared test.</p></fn><fn><p>T, docetaxel; P, cisplatin; F, 5-FU; ERE, early response evaluation; IC-1, 1st cycle induction chemotherapy; ETSS, endoscopic estimated tumor surface shrinkage; N/A, not available; TL, total laryngectomy.</p></fn><fn id="fnT1_1"><label>a</label><p>Discontinuation of per-protocol treatment due to therapy-related severe adverse event (G3 anaphylactic reaction to Erbitux<sup>&#174;</sup>, treated outside protocol with concurrent chemo-radiotherapy with 300 mg/m<sup>2</sup> cisplatin and 69.6 Gy).</p></fn></table-wrap-foot></table-wrap><p>Overall, the common risk factors including the Charlson comorbidity index were equally distributed among arms A and B, allowing for a reliable comparison of outcome in arm A <italic toggle="yes">vs</italic>. arm B.</p><p>Of 52 patients, 25 patients were randomized to the study arm (arm B) with the addition of cetuximab weekly to the regular treatment with TP(F) IC and 27 into arm A (control). A total of 39 patients were considered to be responders to IC-1 according to ETSS &#8805; 30% in early response evaluation and consequently selected for the LOP attempt and further IC cycles. Recommending early TL to non-responders with ETSS &lt; 30% after IC-1 (<italic toggle="yes">n</italic> = 6 in arm A and <italic toggle="yes">n</italic> = 4 in arm B), five patients in arm A and three patients in arm B underwent early TL. In five cases, TL within 12 months (i.e., salvage TL) was performed. In total, <italic toggle="yes">n</italic> = 9 patients received late TL within 24 months of follow-up time.</p><p>Within 3,769 months of follow-up (mean 72.5, median 63.2, SD 49.8, range 1.6&#8211;148 months), 36 patients died (61.5%): 11 patients died from cancer-associated reasons, 21 from non-cancer-related reasons, and four died from another tumor entity.</p><p>Patients receiving cetuximab (arm B) had improved 125-month OS compared to those without (<italic toggle="yes">p</italic> = 0.023; <xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>). The mean OS in arm A was 64.2 (95% CI 46.1&#8211;82.3) months, while the median OS was 56.9 (95% CI 26.1&#8211;87.7) months; the mean OS in arm B was 92.2 (95% CI 75.7&#8211;108.7) months, while the median OS was not reached. DSS and TSS did not differ significantly between arms. However, NCRS was inferior in arm A (without E; <italic toggle="yes">p</italic> = 0.018). The Kaplan&#8211;Meier curves for OS, DSS, TSS, and NCRS for arm A <italic toggle="yes">vs</italic>. arm B are shown in <xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>.</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>Outcome of DeLOS-II patients according to the treatment arm A <italic toggle="yes">vs.</italic> arm B. Kaplan&#8211;Meier cumulative survival plots for <bold>(A)</bold> overall survival (OS), <bold>(B)</bold> disease-specific survival (DSS), <bold>(C)</bold> tumor-specific survival (TSS), and <bold>(D)</bold> non-cancer-related survival (NCRS) among 52 DeLOS-II patients including patients at risk and number of events are shown together with <italic toggle="yes">p</italic>-values from two-sided log-rank tests.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-14-1506840-g001.jpg"/></fig><p>In contrast to significant effects from cetuximab, receiving TP or TPF as chemotherapy backbone did not influence survival significantly (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2</bold>
</xref>). As 5-FU caused severe acute toxicity and even therapy-related deaths, it was omitted from the study protocol during the course of the trial. There obviously were differences between TPF and TP according to slight superiority in TSS and DSS, whereas NCRS (based on the attribution of the early deaths as treatment-related) was inferior. Overall, there was no survival benefit detectable from TPF <italic toggle="yes">vs</italic>. TP.</p><fig position="float" id="f2" orientation="portrait"><label>Figure&#160;2</label><caption><p>Outcome of DeLOS-II patients according to the induction-chemotherapy backbone TPF <italic toggle="yes">vs.</italic> TP. Kaplan&#8211;Meier cumulative survival plots for <bold>(A)</bold> overall survival (OS), <bold>(B)</bold> disease-specific survival (DSS), <bold>(C)</bold> tumor-specific survival (TSS), and <bold>(D)</bold> non-cancer-related survival (NCRS) among 52 DeLOS-II patients including patients at risk and number of events are shown together with <italic toggle="yes">p</italic>-values from two-sided log-rank tests. T, docetaxel; P, cisplatin; F, 5-fluorouracil.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-14-1506840-g002.jpg"/></fig><p>
<xref rid="f3" ref-type="fig">
<bold>Figure&#160;3</bold>
</xref> shows cumulative survival plots for the exact treatment (TP <italic toggle="yes">vs</italic>. TPE <italic toggle="yes">vs</italic>. TPF <italic toggle="yes">vs</italic>. TPFE) according to OS, TSS, DSS, and NCRS. Patients receiving one of the four treatment combinations were found to have only insignificantly deviating outcomes regarding DSS, TSS, and NCRS (all <italic toggle="yes">p</italic> &#8805; 0.129), whereas OS tended to be different (<italic toggle="yes">p</italic> = 0.096). Indeed, pairwise comparisons revealed that receiving TP resulted in an impaired OS compared to TPE (<italic toggle="yes">p</italic> = 0.020; <xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>).</p><fig position="float" id="f3" orientation="portrait"><label>Figure&#160;3</label><caption><p>Outcome of DeLOS-II patients according to the exact treatment applied according to treatment arm A (without cetuximab) <italic toggle="yes">vs.</italic> B (receiving cetuximab) and induction-chemotherapy backbone TPF (before amendment 2) <italic toggle="yes">vs.</italic> TP (omission of 5-FU after amendment 2) resulting in TP, TPE, TPF, and TPFE. Kaplan&#8211;Meier cumulative survival plots for <bold>(A)</bold> overall survival (OS), <bold>(B)</bold> disease-specific survival (DSS), <bold>(C)</bold> tumor-specific survival (TSS), and <bold>(D)</bold> non-cancer-related survival (NCRS) among 52 DeLOS-II patients including patients at risk and number of events are shown together with <italic toggle="yes">p</italic>-values from two-sided log-rank tests. T, docetaxel; P, cisplatin; F, 5-fluorouracil; E, cetuximab.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-14-1506840-g003.jpg"/></fig><table-wrap position="float" id="T2" orientation="portrait"><label>Table&#160;2</label><caption><p>Comparison of mean [95% confidence interval (95% CI)], median (95% CI), and 75th percentile (95% CI) of overall survival (OS), non-cancer-related survival (NCRS), disease-specific survival (DSS), and tumor-specific survival (TSS) in DeLOS-II patients according to treatment arm and induction-chemotherapy backbone and two-sided <italic toggle="yes">p</italic>-values from log-rank tests for pairwise comparison of Kaplan&#8211;Meier cumulative survival curves.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="2" align="left" colspan="1">
</th><th valign="bottom" rowspan="2" align="left" colspan="1">
</th><th valign="bottom" rowspan="2" align="center" colspan="1">Mean (95% CI)</th><th valign="bottom" rowspan="2" align="center" colspan="1">Median (95% CI)</th><th valign="bottom" align="center" rowspan="1" colspan="1">75th percentile</th><th valign="bottom" align="center" rowspan="1" colspan="1">TP</th><th valign="bottom" align="center" rowspan="1" colspan="1">TPE</th><th valign="bottom" align="center" rowspan="1" colspan="1">TPF</th><th valign="bottom" align="center" rowspan="1" colspan="1">TPFE</th></tr><tr><th valign="bottom" align="center" rowspan="1" colspan="1">(95% CI)</th><th valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>-Value</th><th valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>-Value</th><th valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>-Value</th><th valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td valign="top" rowspan="5" align="left" colspan="1">
<bold>OS</bold>
</td><td valign="bottom" align="left" rowspan="1" colspan="1">TP</td><td valign="bottom" align="center" rowspan="1" colspan="1">58.9 (36.4&#8211;81.4)</td><td valign="bottom" align="center" rowspan="1" colspan="1">40.9 (0&#8211;86.8)</td><td valign="bottom" align="center" rowspan="1" colspan="1">20.7 (0&#8211;44.5)</td><td valign="bottom" align="center" rowspan="1" colspan="1">&#8211;</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<bold>0.020</bold>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.425</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.108</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">TPE</td><td valign="bottom" align="center" rowspan="1" colspan="1">95.2 (74.3&#8211;116.2)</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Not reached</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">40.4 (18&#8211;62.8)</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<bold>0.020</bold>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">&#8211;</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.205</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.666</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">TPF</td><td valign="bottom" align="center" rowspan="1" colspan="1">71.7 (42.4&#8211;100.9)</td><td valign="bottom" align="center" rowspan="1" colspan="1">86.2 (16.7&#8211;155.7)</td><td valign="bottom" align="center" rowspan="1" colspan="1">9.7 (0&#8211;57.2)</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.425</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.205</td><td valign="bottom" align="center" rowspan="1" colspan="1">&#8211;</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.464</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">TPFE</td><td valign="bottom" align="center" rowspan="1" colspan="1">87.8 (61.4&#8211;114.2)</td><td valign="bottom" align="center" rowspan="1" colspan="1">104.1 (25.9&#8211;182.3)</td><td valign="bottom" align="center" rowspan="1" colspan="1">69.9 (0&#8211;191.5)</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.108</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.666</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.464</td><td valign="bottom" align="center" rowspan="1" colspan="1">&#8211;</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<italic toggle="yes">Total</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">77.8 (64.9&#8211;90.6)</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">86.2 (39&#8211;133.4)</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">28.9 (14.6&#8211;43.2)</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
</td></tr><tr><td valign="top" rowspan="5" align="left" colspan="1">
<bold>NCRS</bold>
</td><td valign="bottom" align="left" rowspan="1" colspan="1">TP</td><td valign="bottom" align="center" rowspan="1" colspan="1">83.6 (57.5&#8211;109.7)</td><td valign="bottom" align="center" rowspan="1" colspan="1">117.1 (28.2&#8211;206)</td><td valign="bottom" align="center" rowspan="1" colspan="1">40.9 (0&#8211;88.5)</td><td valign="bottom" align="center" rowspan="1" colspan="1">&#8211;</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.074</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.846</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.175</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">TPE</td><td valign="bottom" align="center" rowspan="1" colspan="1">110.9 (93.8&#8211;128.1)</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Not reached</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">121.5 (0&#8211;277.1)</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.074</td><td valign="bottom" align="center" rowspan="1" colspan="1">&#8211;</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.065</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.943</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">TPF</td><td valign="bottom" align="center" rowspan="1" colspan="1">77.9 (48.1&#8211;107.6)</td><td valign="bottom" align="center" rowspan="1" colspan="1">86.2 (26.3&#8211;146.1)</td><td valign="bottom" align="center" rowspan="1" colspan="1">9.7 (0&#8211;85.6)</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.846</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.065</td><td valign="bottom" align="center" rowspan="1" colspan="1">&#8211;</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.135</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">TPFE</td><td valign="bottom" align="center" rowspan="1" colspan="1">108.7 (86.6&#8211;130.8)</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Not reached</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">104.1 (0&#8211;276.3)</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.175</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.943</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.135</td><td valign="bottom" align="center" rowspan="1" colspan="1">&#8211;</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<italic toggle="yes">Total</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">96.1 (83.6&#8211;108.6)</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Not reached</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">60.2 (10.6&#8211;109.8)</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
</td></tr><tr><td valign="top" rowspan="5" align="left" colspan="1">
<bold>DSS</bold>
</td><td valign="bottom" align="left" rowspan="1" colspan="1">TP</td><td valign="bottom" align="center" rowspan="1" colspan="1">87.8 (61.7&#8211;114)</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Not reached</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">26.6 (0&#8211;58.4)</td><td valign="bottom" align="center" rowspan="1" colspan="1">&#8211;</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.145</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.199</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.342</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">TPE</td><td valign="bottom" align="center" rowspan="1" colspan="1">112 (95.3&#8211;128.7)</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Not reached</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Not reached</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.145</td><td valign="bottom" align="center" rowspan="1" colspan="1">&#8211;</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.893</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.657</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">TPF</td><td valign="bottom" align="center" rowspan="1" colspan="1">114 (93.8&#8211;134.2)</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Not reached</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Not reached</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.199</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.893</td><td valign="bottom" align="center" rowspan="1" colspan="1">&#8211;</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.623</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">TPFE</td><td valign="bottom" align="center" rowspan="1" colspan="1">105.7 (81.9&#8211;129.5)</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Not reached</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">71.4 (0&#8211;134.5)</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.342</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.657</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.623</td><td valign="bottom" align="center" rowspan="1" colspan="1">&#8211;</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<italic toggle="yes">Total</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">103.9 (92.2&#8211;115.5)</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Not reached</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Not reached</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
</td></tr><tr><td valign="top" rowspan="5" align="left" colspan="1">
<bold>TSS</bold>
</td><td valign="bottom" align="left" rowspan="1" colspan="1">TP</td><td valign="bottom" align="center" rowspan="1" colspan="1">83.7 (58.4&#8211;108.9)</td><td valign="bottom" align="center" rowspan="1" colspan="1">104.8 (11.8&#8211;197.8)</td><td valign="bottom" align="center" rowspan="1" colspan="1">26.6 (0&#8211;58.4)</td><td valign="bottom" align="center" rowspan="1" colspan="1">&#8211;</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.133</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.117</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.351</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">TPE</td><td valign="bottom" align="center" rowspan="1" colspan="1">106.4 (87.7&#8211;125.2)</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Not reached</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Not reached</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.133</td><td valign="bottom" align="center" rowspan="1" colspan="1">&#8211;</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.632</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.605</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">TPF</td><td valign="bottom" align="center" rowspan="1" colspan="1">114 (93.8&#8211;134.2)</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Not reached</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Not reached</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.117</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.632</td><td valign="bottom" align="center" rowspan="1" colspan="1">&#8211;</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.398</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">TPFE</td><td valign="bottom" align="center" rowspan="1" colspan="1">99.9 (75.9&#8211;123.9)</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Not reached</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">71.4 (8.3&#8211;134.5)</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.351</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.605</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.398</td><td valign="bottom" align="center" rowspan="1" colspan="1">&#8211;</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<italic toggle="yes">Total</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">99.4 (87.4&#8211;111.4)</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">Not reached</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<italic toggle="yes">69.9 (6.7&#8211;133.1)</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>T, docetaxel; P, cisplatin; F, 5-fluorouracil; E, cetuximab. Significant <italic toggle="yes">p</italic> values &lt; 0.05 highlighted bold.</p></fn></table-wrap-foot></table-wrap><p>Comparing the mean and median of the four survival parameters OS, DSS, TSS, and NCRS, only TPE emerged as significantly superior to TP. However, we consistently detected numerically longer mean, median, and 75th percentiles for OS in TPFE and TPE (<xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>).</p><p>Comparing numbers and percentage of patients alive with a functioning larynx, alive after TL, or deceased with a larynx at place or after TL and summarizing data for either LOP or being alive after 125 months (<xref rid="T3" ref-type="table">
<bold>Table&#160;3</bold>
</xref>), a consistent superiority of patients treated in arm B is obvious. Despite the low numbers of patients per treatment, a doubled frequency of patients alive at 125 months with a functioning larynx (44%) and 56% survivors in arm B compared to 22% and 30% in arm A point to a benefit gained through addition of cetuximab to IC with TP(F) followed by RT.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table&#160;3</label><caption><p>Comparison of outcome of DeLOS-II patients 125 months after treatment indicated including larynx organ preservation and survival status at 125 months.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" rowspan="2" align="left" colspan="1">
</th><th valign="top" align="left" rowspan="1" colspan="1">Alive with larynx</th><th valign="top" align="left" rowspan="1" colspan="1">Alive without larynx</th><th valign="top" align="left" rowspan="1" colspan="1">Dead with larynx</th><th valign="top" align="left" rowspan="1" colspan="1">Dead without larynx</th><th valign="top" align="left" rowspan="1" colspan="1">LOP</th><th valign="top" align="left" rowspan="1" colspan="1">Alive at 125 months</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic> (%)
</th><th valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic> (%)
</th><th valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic> (%)
</th><th valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic> (%)
</th><th valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic> (%)
</th><th valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic> (%)
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>TP</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">3 (18.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (6.3)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (50.0)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (25.0)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (68.8)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (25.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>TPE</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">7 (46.7)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (13.3)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (20.0)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (20.0)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (66.7)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (60.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>TPF</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">3 (27.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (9.1)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (36.4)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (27.3)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (63.6)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (36.6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>TPFE</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">4 (40.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (10.0)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (30.0)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (20.0)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (70.0)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (50.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>TP<sup>#</sup>
</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">10 (32.3)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (9.7)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (35.5)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (22.6)</td><td valign="top" align="left" rowspan="1" colspan="1">21 (67.7)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (41.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>TPF<sup>#</sup>
</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">7 (33.3)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (9.5)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (33.3)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (23.8)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (66.7)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (42.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>A</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">6 (22.2)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (7.4)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (44.4)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (25.9)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (66.7)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (29.6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>B</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">11 (44.0)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (12.0)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (24.0)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (20.0)</td><td valign="top" align="left" rowspan="1" colspan="1">17 (68.0)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (56.0)</td></tr></tbody></table><table-wrap-foot><fn><p>Shown are number (percentage) among 52 patients (16, 15, 11, and 10 in TP, TPE, TPF, and TPFE groups of treatment, respectively; 21 and 31 in TPF and TP, respectively; and 27 and 25 in arms A and B, respectively).</p></fn><fn><p>T, docetaxel; P, cisplatin; F, 5-fluorouracil; E, cetuximab; LOP, larynx organ preservation.</p></fn><fn><p>
<bold>
<sup>#</sup>
</bold>Induction-chemotherapy backbone before and after amendment 2 of the DeLOS-II protocol.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>Now, available long-term follow-up data of 52 consecutively accrued DeLOS-II patients demonstrate superior OS of patients treated in arm B (<italic toggle="yes">p</italic> = 0.023) predominantly linked to improved NCRS (<italic toggle="yes">p</italic> = 0.018) due to reduced frequency of deaths from other causes, whereas DSS was numerically superior without reaching statistical significance. There were no significant differences in OS, TSS, DSS, and NCRS (all <italic toggle="yes">p</italic> &#8805; 0.428) related to the IC backbone, TPF <italic toggle="yes">versus</italic> TP. However, we detected significant survival differences in the orthogonal analysis of arm <italic toggle="yes">vs</italic>. IC backbone with, for example, superior OS achieved by TPE compared to TP (<xref rid="T2" ref-type="table">
<bold>Tables&#160;2</bold>
</xref>, <xref rid="T3" ref-type="table">
<bold>3</bold>
</xref>).</p><p>Altogether, patients presenting with LA LHSCC have an unfavorable outcome. In many cases, TL is the only surgical technique to achieve a complete tumor resection. Because of the need for a tracheostomy, the loss of the natural voice function after TL, and the presumably negative impact on quality of life, LOP attempts are of great interest to ear, nose and throat (ENT) surgeons and oncologists as well as their patients. CRT is a comparable alternative to TL followed by adjuvant therapy, except for patients with cT4a LHSCC (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>), as they seem to experience higher recurrence rates when treated with CRT instead of TL + adjuvant therapy. In contrast, within analyses of the DeLOS-II trial data, survival and LOP rates were not inferior for all patients with T4 tumors (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>), provided an ETSS &#8805; 30% in ERE in week 4 after IC-1 is achieved, and can be recommended also for T4 hypopharynx cancer. As prospective comparisons between the different treatment protocols are rare [except for the Radiation Therapy Oncology Group (RTOG) 91-11 study (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B21" ref-type="bibr">21</xref>)], a propensity score-matched analysis of patients treated with Op + PORT, Op + PORCT, CRT, or the DeLOS-II protocol showed the non-inferiority (by showing superiority of DELOS-II regarding OS, TSS, and NCRS) of the LOP protocol according to DeLOS-II (<xref rid="B16" ref-type="bibr">16</xref>), questioning the non-inferiority of CRT compared to which TL once more, as discussed by Licitra et&#160;al. (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>).</p><p>Within the DeLOS-II trial aiming at LOP, IC followed by RT in responders after response evaluation after IC-1 and TL followed by adjuvant therapy in non-responders were recommended to patients with LA LHSCC. While ERE and achieving ETSS &#8805; 30% were highly predictive for cure and LOP (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>), even survival of non-responders treated with early TL after IC-1 was superior to that of CRT or TL + PORT and equal to that of TL + PORCT (<xref rid="B16" ref-type="bibr">16</xref>). Moreover, ERE after IC-1 helps prevent prolonged administration of an ineffective treatment to the patient and helps prevent salvage surgery with its well-known high complication rates and impossibility of curatively resecting the cancer in inappropriately high frequency (<xref rid="B23" ref-type="bibr">23</xref>).</p><p>As reported for the per-protocol defined outcome analysis of the whole DeLOS-II trial after 24 months, the study arm with patients receiving cetuximab failed to be superior to the standard arm without cetuximab. The primary endpoint 24-month LFS [both arms with LFS &gt; 35%, arm A (40/85, 47.1%) and arm B (41/88, 46.6%)] and the secondary endpoint 24-month OS (arm A 68.2% and arm B 69.3%) were not different. This, however, could be related to the per-protocol defined 24-month follow-up that could be too short to identify outcome differences and even more long-term outcomes of patients.</p><p>In the present study, we provide long-term follow-up data of the patients treated at the University Hospital Leipzig participating in the DeLOS-II study. Surprisingly, after 60 months and especially after 125 months, patients who received cetuximab had significantly better OS than those without. There was no difference between IC with TP and IC with TPF. Analyzing DSS and TSS, patients benefitted from receiving E without statistical significance. In line with this finding, the frequency of relapse, distant metastasis and occurence of other malignancies demonstrate the same (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table S1</bold>
</xref>, available online). In the long-term, death from other, non-cancer-related causes becomes more impactful and differs significantly in our cohort with benefits for the patients who received cetuximab. In analyses of survival measures, competing risk factors have to be considered. Paying attention to this fact, we analyzed OS by censoring cancer-related deaths in addition to the commonly accepted right-censoring of patients alive at the last follow-up. As age- and senescence-related differences between arms or exact treatment were found to be without significance, the significant differences between arms regarding non-cancer-related survival by only calculating log-rank tests considering death from other causes (not related to cancer) as event appear to be important. Possible confounding of comorbidities was excluded here, as severe comorbidities were an exclusion criterion for DeLOS-II participation (<xref rid="B14" ref-type="bibr">14</xref>). Also retrospectively assessing the presence of any comorbidities with a known impact on survival by applying the Charlson score (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>), there was no difference between arms (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>). The causality of the observed association between NCRS and cetuximab remains unclear. Cetuximab enhances the antitumor immune response through the activation of NK cells and facilitates their interaction with tumor cells. Promising, but yet without approval, is the combination of cetuximab and pembrolizumab to overcome cetuximab resistance as shown in <italic toggle="yes">ex vivo</italic> experiments (<xref rid="B26" ref-type="bibr">26</xref>). Approved for HNSCC, the anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody cetuximab (E) is used for system treatment of recurrent or metastatic (R/M) HNSCC alone or in combination with PF [EXTREME (<xref rid="B27" ref-type="bibr">27</xref>&#8211;<xref rid="B29" ref-type="bibr">29</xref>)] or TP [TPExtreme (<xref rid="B30" ref-type="bibr">30</xref>) within the TREMPLIN-II study (<xref rid="B31" ref-type="bibr">31</xref>)], IC with TPF followed by radiochemotherapy with three more cycles P or bioradiotherapy with E weekly showed no significant differences in LOP and OS. However, because of a high dropout rate of 24% and thus, high selection bias, comparison with other LOP trials is questionable. TREMPLIN-II was conducted to choose an experimental arm to compare to the GORTEC 2000-01 trial (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B32" ref-type="bibr">32</xref>); as none of the arms was superior to the other, no further study in this regard was attempted.</p><p>Several studies on LOP using IC report similar OS rates. Mattei et&#160;al. (<xref rid="B9" ref-type="bibr">9</xref>) reported in a retrospective study with patients suffering from LA hypopharyngeal cancer only resectable via TL administered with TPF IC followed by RT with or without cisplatin or cetuximab a 5-year OS of 54%. In this study, the T4 category was a negative predictor for OS.</p><p>The milestone trial RTOG 91-11 (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>) prospectively randomized patients into different treatment regimens consisting of IC + RT, CRT, or RT alone between 1992 and 2000. They report a 5-year OS of 58.1% and a 10-year OS of 38.8% (<xref rid="B2" ref-type="bibr">2</xref>). LOP was 67.5% after 10-year follow-up (FU), matching exactly the above-reported LOP data in arms A and B in <xref rid="T3" ref-type="table">
<bold>Table&#160;3</bold>
</xref>.</p><p>Pointreau et&#160;al. (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B32" ref-type="bibr">32</xref>) found 60-month OS of 51% and 120-month OS of 30% comparing survival rates of 213 patients administered with three cycles of IC with either TPF or PF followed by radio(chemo)therapy for responders or laryngectomy for non-responders. The authors recommend IC with TPF, as there were higher rates of LOP compared to PF only. This is in line with the findings of Vermorken et&#160;al., who described a survival benefit when applying TPF instead of PF only in patients with unresectable LHSCC (<xref rid="B33" ref-type="bibr">33</xref>).</p><p>However, the 60-month OS rate in the cohort of 52 DeLOS-II patients with 71.8% in arm B administered with TPE or TPFE was clearly superior. After 125-month FU, the OS rate was still 56.0%, differing significantly from the 29.6% in the TP/TPF group (arm A; <xref rid="T3" ref-type="table">
<bold>Table&#160;3</bold>
</xref>) and according to the log-rank test (<italic toggle="yes">p</italic> = 0.023; <xref rid="f1" ref-type="fig">
<bold>Figure&#160;1A</bold>
</xref>), clearly surpassing the survival data of comparable studies mentioned above (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B33" ref-type="bibr">33</xref>).</p><p>The long-term outcomes of the complete cohort of DeLOS-II patients would have been desirable but unfortunately could not be obtained. Reflecting 30.1% (52/173) of the complete study cohort, our results still suggest a potential additional benefit when adding cetuximab to the IC, the RT, and 6 months in total to the DeLOS-II protocol. Further studies are needed, preferably randomized controlled trials (RCTs), to find out and evaluate the best treatment protocol for LOP attempts only via TL R0-resectable LHSCC patients. Other agents promising a treatment benefit should be examined. For instance, pembrolizumab is known and approved for the treatment of R/M HNSCC because of its antitumor effect that is enriched in HNSCC patients with a certain level of PD-L1 expression in their tumor. The tumor proportion score (TPS) is calculated as the percentage of cells staining positive for PD-L1 in immunohistochemistry among tumor cells, and the combined positive score (CPS) also considers immune cells (<xref rid="B34" ref-type="bibr">34</xref>); after KEYNOTE-048 (<xref rid="B35" ref-type="bibr">35</xref>), pembrolizumab is approved for R/M HNSCC with CPS &#8805; 1 (which of course includes TPS &#8805; 50%). KEYNOTE-689 investigates in LA HNSCC with CPS &#8805; 1 the neoadjuvant treatment with two cycles of pembrolizumab upfront surgery followed by a further 15 cycles of pembrolizumab during adjuvant radiotherapy &#177; cisplatin (<xref rid="B36" ref-type="bibr">36</xref>). The European Larynx Organ Preservation Study [ELOS (<xref rid="B37" ref-type="bibr">37</xref>)] investigates the effect of pembrolizumab when added to IC with TP followed by RT according to the DeLOS-II protocol. It remains to be shown if replacing cetuximab with pembrolizumab enables higher LOP and OS rates.</p><p>One strength of our study is the high number of participants per subgroup accrued and treated within a prospectively designed RCT at a single University Hospital. This led to 1) homogeneity in decision-making for participation in the LOP trial according to uniform per-protocol defined inclusion and exclusion criteria, 2) random assignment to pre-defined treatment groups while stratifying according to characteristics/covariates with the highest impact on outcome, 3) response evaluation according to the protocol-defined ERE criteria by a well-trained single ENT surgeon familiar with LOP, 4) regular follow-up of patients according to the National Comprehensive Cancer Network (NCCN) and national guidelines, 5) regular monitoring of organ function and health-related quality of life utilizing patient-reported outcome measures (PROM) using OncoFunction (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>) to detect early signs of functional impairment, and 6) high quality of documentation attributed to study patients. In addition to these strengths, there are limitations that have to be considered. Our results were achieved in (according to inclusion and exclusion criteria) highly selected patients suffering from a rare disease. Despite allowing for the detection of significant differences between groups, the number of patients in each of the treatment groups was rather low with &lt;30 patients in each subgroup analyzed. This increases the possibility of random effects and, in particular, increases the false-positive reporting probability (FPRP) of (additionally in tendency rather to high) effect estimates, as small samples favor the overrepresentation of extreme distributions. Rather few patients per treatment may have caused a positive reporting bias that we cannot exclude. An increased FPRP could even more be expected, as the exploratory analyses of outcome measures were not pre-planned/scheduled within the DeLOS-II protocol and especially were not considered in the power calculation for the DeLOS-II trial. Because of the rather low accrual of patients in the other 22 DeLOS-II study centers, we accrued the highest number of DeLOS-II patients treated in our center and had the unique opportunity to assess long-term outcomes with sufficiently high numbers of patients per treatment in a unique environment. Our patients were treated in a certified tertiary tumor center of excellence, the Comprehensive Cancer Center Central Germany (CCCG). The CCCG has an infrastructure allowing for high-quality patient-centered workflows with professionalized interaction of all disciplines involved in diagnostic, treatment, and follow-up monitoring of head and neck cancer patients, patients who are always a special group of LA LHSCC patients with special and often unmet needs. Assessing these special needs (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>) during prolonged follow-up and addressing them adequately may have contributed to the overall good outcome. Building such infrastructure requires time and dedicated professionals in each of the clinics and institutes involved but especially dedicated consultation hours regularly utilizing the adequate tools (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>). Such an environment could hardly be immediately established in any clinic. Therefore, the results reported here may not be representative of results that can be easily achieved anywhere by <italic toggle="yes">ad hoc</italic> starting the LOP approach for every patient with LA LHSCC amenable for TL by applying (potentially without the availability of the infrastructure required) the treatment according to the DeLOS-II protocol utilizing TPE IC. The ERE after IC-1 assessing ETSS for decision-making for treatment with either TL or further IC followed by radiotherapy requires familiarity with the approach and hence an adequate training.</p><p>However, the superior survival in DeLOS-II patients treated with cetuximab and especially TPE points to a so far not reported benefit from cetuximab in LOP approaches, which deserves further investigation, for instance, in a LOP trial combining TPE IC with blockade of the PD-1:PD-L1 immune checkpoint by, for example, pembrolizumab or another monoclonal anti-PD-1 antibody. The LOP approach may additionally benefit from molecular and genetic analyses (<xref rid="B40" ref-type="bibr">40</xref>&#8211;<xref rid="B42" ref-type="bibr">42</xref>). Even a tailored approach according to a comprehensive predictive classifier integrating clinical, molecular, and multiomics data for personalized treatment decisions enhancing response to IC, to achieve LOP in a further increased frequency of patients (<xref rid="B43" ref-type="bibr">43</xref>), has the potential to result in long-term survival with good health-related quality of life, altogether the ultimate goals of preventive, predictive, and personalized medicine.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank all patients and their families who participated in the investigation. We especially thank all contributing physicians for providing clinical data and the entire technical staff, all nurses, and physicians in the involved departments. We acknowledge support from Leipzig University for Open Access Publishing.</p></ack><sec sec-type="data-availability" id="s5"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="s6"><title>Ethics statement</title><p>The studies involving humans were approved by Ethics Committee of the Medical Faculty of the University Leipzig (votes 166-07-12072006, 201&#8211;10-12072010, and 202-10-12072010). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>GW: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Supervision, Validation, Visualization, Writing &#8211; original draft, Writing &#8211; review &amp; editing. TW: Data curation, Formal analysis, Investigation, Supervision, Validation, Visualization, Writing &#8211; original draft, Writing &#8211; review &amp; editing. VZ: Writing &#8211; review &amp; editing. MS: Writing &#8211; review &amp; editing. MP: Writing &#8211; review &amp; editing. SW: Resources, Supervision, Validation, Writing &#8211; review &amp; editing. VK: Supervision, Validation, Writing &#8211; review &amp; editing. AD: Resources, Supervision, Validation, Writing &#8211; review &amp; editing.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors GW, SW, and AD declare that financial support was received for the research, authorship, and/or publication of this article. DeLOS-II was an investigator-initiated larynx organ preservation, phase 2, randomized trial sponsored by Leipzig University and supported by unrestricted educational grants from Merck, Darmstadt, Germany, and Sanofi, Berlin, Germany. No grant number is applicable. Merck and Sanofi had no influence on the design of the study and collection, analysis, and interpretation of data and in writing this manuscript.</p><p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p></sec><sec sec-type="ai-statement" id="s10"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="s12"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fonc.2024.1506840/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fonc.2024.1506840/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table1.pdf" position="float" orientation="portrait"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forastiere</surname><given-names>AA</given-names></name><name name-style="western"><surname>Goepfert</surname><given-names>H</given-names></name><name name-style="western"><surname>Maor</surname><given-names>M</given-names></name><name name-style="western"><surname>Pajak</surname><given-names>TF</given-names></name><name name-style="western"><surname>Weber</surname><given-names>R</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer</article-title>. <source>N Engl J Med</source>. (<year>2003</year>) <volume>349</volume>:<page-range>2091&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa031317</pub-id><pub-id pub-id-type="pmid">14645636</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forastiere</surname><given-names>AA</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Weber</surname><given-names>RS</given-names></name><name name-style="western"><surname>Maor</surname><given-names>MH</given-names></name><name name-style="western"><surname>Goepfert</surname><given-names>H</given-names></name><name name-style="western"><surname>Pajak</surname><given-names>TF</given-names></name><etal/></person-group>. <article-title>Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer</article-title>. <source>J Clin Oncol</source>. (<year>2013</year>) <volume>31</volume>:<page-range>845&#8211;52</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1200/JCO.2012.43.6097</pub-id><pub-id pub-id-type="pmcid">PMC3577950</pub-id><pub-id pub-id-type="pmid">23182993</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolf</surname><given-names>GT</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>SG</given-names></name><name name-style="western"><surname>Hong</surname><given-names>WK</given-names></name><name name-style="western"><surname>Hillman</surname><given-names>R</given-names></name><name name-style="western"><surname>Spaulding</surname><given-names>M</given-names></name><name name-style="western"><surname>Laramore</surname><given-names>GE</given-names></name><etal/></person-group>. <article-title>Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer</article-title>. <source>N Engl J Med</source>. (<year>1991</year>) <volume>324</volume>:<page-range>1685&#8211;90</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJM199106133242402</pub-id><pub-id pub-id-type="pmid">2034244</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vermorken</surname><given-names>JB</given-names></name><name name-style="western"><surname>Remenar</surname><given-names>E</given-names></name><name name-style="western"><surname>van Herpen</surname><given-names>C</given-names></name><name name-style="western"><surname>Gorlia</surname><given-names>T</given-names></name><name name-style="western"><surname>Mesia</surname><given-names>R</given-names></name><name name-style="western"><surname>Degardin</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer</article-title>. <source>N Engl J Med</source>. (<year>2007</year>) <volume>357</volume>:<page-range>1695&#8211;704</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa071028</pub-id><pub-id pub-id-type="pmid">17960012</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Posner</surname><given-names>MR</given-names></name><name name-style="western"><surname>Hershock</surname><given-names>DM</given-names></name><name name-style="western"><surname>Blajman</surname><given-names>CR</given-names></name><name name-style="western"><surname>Mickiewicz</surname><given-names>E</given-names></name><name name-style="western"><surname>Winquist</surname><given-names>E</given-names></name><name name-style="western"><surname>Gorbounova</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer</article-title>. <source>N Engl J Med</source>. (<year>2007</year>) <volume>357</volume>:<page-range>1705&#8211;15</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa070956</pub-id><pub-id pub-id-type="pmid">17960013</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pointreau</surname><given-names>Y</given-names></name><name name-style="western"><surname>Garaud</surname><given-names>P</given-names></name><name name-style="western"><surname>Chapet</surname><given-names>S</given-names></name><name name-style="western"><surname>Sire</surname><given-names>C</given-names></name><name name-style="western"><surname>Tuchais</surname><given-names>C</given-names></name><name name-style="western"><surname>Tortochaux</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation</article-title>. <source>J Natl Cancer Inst</source>. (<year>2009</year>) <volume>101</volume>:<fpage>498</fpage>&#8211;<lpage>506</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/jnci/djp007</pub-id><pub-id pub-id-type="pmid">19318632</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dietz</surname><given-names>A</given-names></name><name name-style="western"><surname>Rudat</surname><given-names>V</given-names></name><name name-style="western"><surname>Dreyhaupt</surname><given-names>J</given-names></name><name name-style="western"><surname>Pritsch</surname><given-names>M</given-names></name><name name-style="western"><surname>Hoppe</surname><given-names>F</given-names></name><name name-style="western"><surname>Hagen</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial)</article-title>. <source>Eur Arch Otorhinolaryngol</source>. (<year>2009</year>) <volume>266</volume>:<page-range>1291&#8211;300</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00405-008-0846-y</pub-id><pub-id pub-id-type="pmid">18972123</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfister</surname><given-names>DG</given-names></name><name name-style="western"><surname>Laurie</surname><given-names>SA</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>GS</given-names></name><name name-style="western"><surname>Mendenhall</surname><given-names>WM</given-names></name><name name-style="western"><surname>Adelstein</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Ang</surname><given-names>KK</given-names></name><etal/></person-group>. <article-title>American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer</article-title>. <source>J Clin Oncol</source>. (<year>2006</year>) <volume>24</volume>:<page-range>3693&#8211;704</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1200/JCO.2006.07.4559</pub-id><pub-id pub-id-type="pmid">16832122</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattei</surname><given-names>P</given-names></name><name name-style="western"><surname>Gal</surname><given-names>J</given-names></name><name name-style="western"><surname>Chamorey</surname><given-names>E</given-names></name><name name-style="western"><surname>Dassonville</surname><given-names>O</given-names></name><name name-style="western"><surname>Poissonnet</surname><given-names>G</given-names></name><name name-style="western"><surname>Aloi</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Docetaxel-cisplatin-fluorouracil induction chemotherapy for larynx preservation in patients with locally advanced hypopharyngeal cancer: predictive factors of oncologic and functional outcomes</article-title>. <source>J Clin Med</source>. (<year>2023</year>) <volume>12</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3390/jcm12031131</pub-id><pub-id pub-id-type="pmcid">PMC9918009</pub-id><pub-id pub-id-type="pmid">36769779</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lefebvre</surname><given-names>J-L</given-names></name><name name-style="western"><surname>Ang</surname><given-names>KK</given-names></name></person-group>. <article-title>Larynx preservation clinical trial design: Key issues and recommendations&#8211;a consensus panel summary</article-title>. <source>Head Neck</source>. (<year>2009</year>) <volume>31</volume>:<page-range>429&#8211;41</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/hed.21081</pub-id><pub-id pub-id-type="pmid">19283793</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grover</surname><given-names>S</given-names></name><name name-style="western"><surname>Swisher-McClure</surname><given-names>S</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>RB</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>PH</given-names></name><etal/></person-group>. <article-title>Total laryngectomy versus larynx preservation for T4a larynx cancer: patterns of care and survival outcomes</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>2015</year>) <volume>92</volume>:<fpage>594</fpage>&#8211;<lpage>601</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ijrobp.2015.03.004</pub-id><pub-id pub-id-type="pmid">26068492</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenthal</surname><given-names>DI</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>ASR</given-names></name><name name-style="western"><surname>Weber</surname><given-names>RS</given-names></name><name name-style="western"><surname>Garden</surname><given-names>AS</given-names></name><name name-style="western"><surname>Sevak</surname><given-names>PR</given-names></name><name name-style="western"><surname>Kies</surname><given-names>MS</given-names></name><etal/></person-group>. <article-title>Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey</article-title>. <source>Cancer</source>. (<year>2015</year>) <volume>121</volume>:<page-range>1608&#8211;19</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/cncr.29241</pub-id><pub-id pub-id-type="pmcid">PMC4424158</pub-id><pub-id pub-id-type="pmid">25586197</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonner</surname><given-names>JA</given-names></name><name name-style="western"><surname>Harari</surname><given-names>PM</given-names></name><name name-style="western"><surname>Giralt</surname><given-names>J</given-names></name><name name-style="western"><surname>Azarnia</surname><given-names>N</given-names></name><name name-style="western"><surname>Shin</surname><given-names>DM</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>RB</given-names></name><etal/></person-group>. <article-title>Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck</article-title>. <source>N Engl J Med</source>. (<year>2006</year>) <volume>354</volume>:<page-range>567&#8211;78</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa053422</pub-id><pub-id pub-id-type="pmid">16467544</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dietz</surname><given-names>A</given-names></name><name name-style="western"><surname>Wichmann</surname><given-names>G</given-names></name><name name-style="western"><surname>Kuhnt</surname><given-names>T</given-names></name><name name-style="western"><surname>Pfreundner</surname><given-names>L</given-names></name><name name-style="western"><surname>Hagen</surname><given-names>R</given-names></name><name name-style="western"><surname>Scheich</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II</article-title>. <source>Ann Oncol</source>. (<year>2018</year>) <volume>29</volume>:<page-range>2105&#8211;14</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/annonc/mdy332</pub-id><pub-id pub-id-type="pmid">30412221</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wichmann</surname><given-names>G</given-names></name><name name-style="western"><surname>Kr&#252;ger</surname><given-names>A</given-names></name><name name-style="western"><surname>Boehm</surname><given-names>A</given-names></name><name name-style="western"><surname>Kolb</surname><given-names>M</given-names></name><name name-style="western"><surname>Hofer</surname><given-names>M</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and (18)F-FDG-PET/CT</article-title>. <source>Eur J Cancer</source>. (<year>2017</year>) <volume>72</volume>:<page-range>144&#8211;55</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ejca.2016.11.013</pub-id><pub-id pub-id-type="pmid">28033526</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wichmann</surname><given-names>G</given-names></name><name name-style="western"><surname>Wald</surname><given-names>T</given-names></name><name name-style="western"><surname>Pirlich</surname><given-names>M</given-names></name><name name-style="western"><surname>Stoehr</surname><given-names>M</given-names></name><name name-style="western"><surname>Zebralla</surname><given-names>V</given-names></name><name name-style="western"><surname>Kuhnt</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Improved survival of locoregional-advanced larynx and hypopharynx cancer patients treated according to the DeLOS-II protocol</article-title>. <source>Front Oncol</source>. (<year>2024</year>) <volume>14</volume>:<elocation-id>1394691</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fonc.2024.1394691</pub-id><pub-id pub-id-type="pmid">38919522</pub-id><pub-id pub-id-type="pmcid">PMC11198870</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaplan</surname><given-names>EL</given-names></name><name name-style="western"><surname>Meier</surname><given-names>P</given-names></name></person-group>. <article-title>Nonparametric estimation from incomplete observations</article-title>. <source>J Am Stat Assoc</source>. (<year>1958</year>) <volume>53</volume>:<page-range>457&#8211;81</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1080/01621459.1958.10501452</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mantel</surname><given-names>N</given-names></name></person-group>. <article-title>Evaluation of survival data and two new rank order statistics arising in its consideration</article-title>. <source>Cancer Chemother Rep</source>. (<year>1966</year>) <volume>50</volume>:<page-range>163&#8211;70</page-range>.<pub-id pub-id-type="pmid">5910392</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>DR</given-names></name></person-group>. <article-title>Regression models and life-tables. Royal statistical society</article-title>. <source>J Ser B: Methodological</source>. (<year>1972</year>) <volume>34</volume>:<fpage>187</fpage>&#8211;<lpage>202</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.2517-6161.1972.tb00899.x</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moons</surname><given-names>KGM</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name><name name-style="western"><surname>Reitsma</surname><given-names>JB</given-names></name><name name-style="western"><surname>Ioannidis</surname><given-names>JP</given-names></name><name name-style="western"><surname>Macaskill</surname><given-names>P</given-names></name><name name-style="western"><surname>Steyerberg</surname><given-names>EW</given-names></name><etal/></person-group>. <article-title>Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration</article-title>. <source>Ann Intern Med</source>. (<year>2015</year>) <volume>162</volume>:<fpage>W1</fpage>&#8211;<lpage>73</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.7326/M14-0698</pub-id><pub-id pub-id-type="pmid">25560730</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dietz</surname><given-names>A</given-names></name><name name-style="western"><surname>Wiegand</surname><given-names>S</given-names></name><name name-style="western"><surname>Kuhnt</surname><given-names>T</given-names></name><name name-style="western"><surname>Wichmann</surname><given-names>G</given-names></name></person-group>. <article-title>Laryngeal preservation approaches: considerations for new selection criteria based on the deLOS-II trial</article-title>. <source>Front Oncol</source>. (<year>2019</year>) <volume>9</volume>:<elocation-id>625</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fonc.2019.00625</pub-id><pub-id pub-id-type="pmid">31355142</pub-id><pub-id pub-id-type="pmcid">PMC6635549</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Licitra</surname><given-names>L</given-names></name><name name-style="western"><surname>Bonomo</surname><given-names>P</given-names></name><name name-style="western"><surname>Sanguineti</surname><given-names>G</given-names></name><name name-style="western"><surname>Bacigalupo</surname><given-names>A</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>GG</given-names></name><name name-style="western"><surname>Valerini</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Different view on larynx preservation evidence-based treatment recommendations</article-title>. <source>J Clin Oncol</source>. (<year>2018</year>) <volume>36</volume>:<page-range>1376&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1200/JCO.2018.77.8001</pub-id><pub-id pub-id-type="pmid">29558275</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Putten</surname><given-names>L</given-names></name><name name-style="western"><surname>Bree</surname><given-names>R</given-names></name><name name-style="western"><surname>Doornaert</surname><given-names>PA</given-names></name><name name-style="western"><surname>Buter</surname><given-names>J</given-names></name><name name-style="western"><surname>Eerenstein</surname><given-names>SE</given-names></name><name name-style="western"><surname>Rietveld</surname><given-names>DH</given-names></name><etal/></person-group>. <article-title>Salvage surgery in post-chemoradiation laryngeal and hypopharyngeal carcinoma: outcome and review</article-title>. <source>Acta Otorhinolaryngol Ital</source>. (<year>2015</year>) <volume>35</volume>:<page-range>162&#8211;72</page-range>.<pub-id pub-id-type="pmcid">PMC4510934</pub-id><pub-id pub-id-type="pmid">26246660</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charlson</surname><given-names>M</given-names></name><name name-style="western"><surname>Szatrowski</surname><given-names>TP</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>J</given-names></name><name name-style="western"><surname>Gold</surname><given-names>J</given-names></name></person-group>. <article-title>Validation of a combined comorbidity index</article-title>. <source>J Clin Epidemiol</source>. (<year>1994</year>) <volume>47</volume>:<page-range>1245&#8211;51</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/0895-4356(94)90129-5</pub-id><pub-id pub-id-type="pmid">7722560</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wald</surname><given-names>T</given-names></name><name name-style="western"><surname>Birnbaum</surname><given-names>K</given-names></name><name name-style="western"><surname>Wiegand</surname><given-names>S</given-names></name><name name-style="western"><surname>Dietz</surname><given-names>A</given-names></name><name name-style="western"><surname>Zebralla</surname><given-names>V</given-names></name><name name-style="western"><surname>Wichmann</surname><given-names>G</given-names></name></person-group>. <article-title>Automatic calculation and visualization of comorbidity scores for decision-making in tumor boards</article-title>. <source>Laryngorhinootologie</source>. (<year>2020</year>) <volume>99</volume>:<page-range>31&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1055/a-1058-0171</pub-id><pub-id pub-id-type="pmid">31791084</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berszin</surname><given-names>M</given-names></name><name name-style="western"><surname>Michaelides</surname><given-names>I</given-names></name><name name-style="western"><surname>Siemert</surname><given-names>J</given-names></name><name name-style="western"><surname>R&#246;hl</surname><given-names>L</given-names></name><name name-style="western"><surname>Wellhausen</surname><given-names>J</given-names></name><name name-style="western"><surname>Wald</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Cytokine profiles of head and neck squamous cell carcinoma undergoing dual immunotherapy with cetuximab and pembrolizumab identify interferon gamma-induced protein 10 as novel biomarker</article-title>. <source>Front Oncol</source>. (<year>2022</year>) <volume>12</volume>:<elocation-id>795277</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fonc.2022.795277</pub-id><pub-id pub-id-type="pmid">35296001</pub-id><pub-id pub-id-type="pmcid">PMC8918678</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vermorken</surname><given-names>JB</given-names></name><name name-style="western"><surname>Mesia</surname><given-names>R</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>F</given-names></name><name name-style="western"><surname>Remenar</surname><given-names>E</given-names></name><name name-style="western"><surname>Kawecki</surname><given-names>A</given-names></name><name name-style="western"><surname>Rottey</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Platinum-based chemotherapy plus cetuximab in head and neck cancer</article-title>. <source>N Engl J Med</source>. (<year>2008</year>) <volume>359</volume>:<page-range>1116&#8211;27</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa0802656</pub-id><pub-id pub-id-type="pmid">18784101</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taberna</surname><given-names>M</given-names></name><name name-style="western"><surname>Oliva</surname><given-names>M</given-names></name><name name-style="western"><surname>Mes&#237;a</surname><given-names>R</given-names></name></person-group>. <article-title>Cetuximab-containing combinations in locally advanced and recurrent or metastatic head and neck squamous cell carcinoma</article-title>. <source>Front Oncol</source>. (<year>2019</year>) <volume>9</volume>:<elocation-id>383</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fonc.2019.00383</pub-id><pub-id pub-id-type="pmid">31165040</pub-id><pub-id pub-id-type="pmcid">PMC6536039</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#252;bbers</surname><given-names>K</given-names></name><name name-style="western"><surname>Pavlychenko</surname><given-names>M</given-names></name><name name-style="western"><surname>Wald</surname><given-names>T</given-names></name><name name-style="western"><surname>Wiegand</surname><given-names>S</given-names></name><name name-style="western"><surname>Dietz</surname><given-names>A</given-names></name><name name-style="western"><surname>Zebralla</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Choosing the right treatment option for the right R/M HNSCC patient: should we adhere to PFE for first-line therapy</article-title>? <source>Front Oncol</source>. (<year>2021</year>) <volume>11</volume>:<elocation-id>715297</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fonc.2021.715297</pub-id><pub-id pub-id-type="pmid">34354955</pub-id><pub-id pub-id-type="pmcid">PMC8329655</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guigay</surname><given-names>J</given-names></name><name name-style="western"><surname>Aup&#233;rin</surname><given-names>A</given-names></name><name name-style="western"><surname>Fayette</surname><given-names>J</given-names></name><name name-style="western"><surname>Saada-Bouzid</surname><given-names>E</given-names></name><name name-style="western"><surname>Lafond</surname><given-names>C</given-names></name><name name-style="western"><surname>Taberna</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial</article-title>. <source>Lancet Oncol</source>. (<year>2021</year>) <volume>22</volume>:<page-range>463&#8211;75</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1470-2045(20)30755-5</pub-id><pub-id pub-id-type="pmid">33684370</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lefebvre</surname><given-names>JL</given-names></name><name name-style="western"><surname>Pointreau</surname><given-names>Y</given-names></name><name name-style="western"><surname>Rolland</surname><given-names>F</given-names></name><name name-style="western"><surname>Alfonsi</surname><given-names>M</given-names></name><name name-style="western"><surname>Baudoux</surname><given-names>A</given-names></name><name name-style="western"><surname>Sire</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study</article-title>. <source>J Clin Oncol</source>. (<year>2013</year>) <volume>31</volume>:<page-range>853&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1200/JCO.2012.42.3988</pub-id><pub-id pub-id-type="pmid">23341517</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janoray</surname><given-names>G</given-names></name><name name-style="western"><surname>Pointreau</surname><given-names>Y</given-names></name><name name-style="western"><surname>Garaud</surname><given-names>P</given-names></name><name name-style="western"><surname>Chapet</surname><given-names>S</given-names></name><name name-style="western"><surname>Alfonsi</surname><given-names>M</given-names></name><name name-style="western"><surname>Sire</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, &#177; Docetaxel for larynx preservation</article-title>. <source>J Natl Cancer Inst</source>. (<year>2016</year>) <volume>108</volume>. doi:&#160;<pub-id pub-id-type="doi">10.1093/jnci/djv368</pub-id><pub-id pub-id-type="pmid">26681800</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Remenar</surname><given-names>E</given-names></name><name name-style="western"><surname>van Herpen</surname><given-names>C</given-names></name><name name-style="western"><surname>Germa Lluch</surname><given-names>J</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>S</given-names></name><name name-style="western"><surname>Gorlia</surname><given-names>T</given-names></name><name name-style="western"><surname>Degardin</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN). Final analysis of EORTC 24971</article-title>. <source>J Clin Oncol</source>. (<year>2006</year>) <volume>24</volume>:<elocation-id>5516</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1200/jco.2006.24.18_suppl.5516</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emancipator</surname><given-names>K</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Aurora-Garg</surname><given-names>D</given-names></name><name name-style="western"><surname>Bal</surname><given-names>T</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>EE</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer</article-title>. <source>Mod Pathol</source>. (<year>2021</year>) <volume>34</volume>:<page-range>532&#8211;41</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41379-020-00710-9</pub-id><pub-id pub-id-type="pmid">33239737</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burtness</surname><given-names>B</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Greil</surname><given-names>R</given-names></name><name name-style="western"><surname>Souli&#232;res</surname><given-names>D</given-names></name><name name-style="western"><surname>Tahara</surname><given-names>M</given-names></name><name name-style="western"><surname>Castro de</surname><given-names>G JR</given-names></name><etal/></person-group>. <article-title>Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study</article-title>. <source>Lancet</source>. (<year>2019</year>) <volume>394</volume>:<page-range>1915&#8211;28</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(19)32591-7</pub-id><pub-id pub-id-type="pmid">31679945</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uppaluri</surname><given-names>R</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>KM</given-names></name><name name-style="western"><surname>Egloff</surname><given-names>AM</given-names></name><name name-style="western"><surname>Zolkind</surname><given-names>P</given-names></name><name name-style="western"><surname>Skidmore</surname><given-names>ZL</given-names></name><name name-style="western"><surname>Nussenbaum</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: A multicenter, phase II trial</article-title>. <source>Clin Cancer Res</source>. (<year>2020</year>) <volume>26</volume>:<page-range>5140&#8211;52</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-1695</pub-id><pub-id pub-id-type="pmcid">PMC7547532</pub-id><pub-id pub-id-type="pmid">32665297</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wichmann</surname><given-names>G</given-names></name><name name-style="western"><surname>Wald</surname><given-names>T</given-names></name><name name-style="western"><surname>Pirlich</surname><given-names>M</given-names></name><name name-style="western"><surname>Napp</surname><given-names>J</given-names></name><name name-style="western"><surname>M&#252;nter</surname><given-names>I</given-names></name><name name-style="western"><surname>Asendorf</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>The european larynx organ preservation study MK-3475-C44</article-title>. <source>Front Oncol</source>. (<year>2024</year>) <volume>14</volume>:<elocation-id>1433238</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fonc.2024.1433238</pub-id><pub-id pub-id-type="pmid">39239277</pub-id><pub-id pub-id-type="pmcid">PMC11374655</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zebralla</surname><given-names>V</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>J</given-names></name><name name-style="western"><surname>Wald</surname><given-names>T</given-names></name><name name-style="western"><surname>Boehm</surname><given-names>A</given-names></name><name name-style="western"><surname>Wichmann</surname><given-names>G</given-names></name><name name-style="western"><surname>Berger</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Obtaining patient-reported outcomes electronically with "OncoFunction" in head and neck cancer patients during aftercare</article-title>. <source>Front Oncol</source>. (<year>2020</year>) <volume>10</volume>:<elocation-id>549915</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fonc.2020.549915</pub-id><pub-id pub-id-type="pmid">33324544</pub-id><pub-id pub-id-type="pmcid">PMC7724103</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zebralla</surname><given-names>V</given-names></name><name name-style="western"><surname>Wiegand</surname><given-names>S</given-names></name><name name-style="western"><surname>Dietz</surname><given-names>A</given-names></name><name name-style="western"><surname>Wichmann</surname><given-names>G</given-names></name><name name-style="western"><surname>Neumuth</surname><given-names>T</given-names></name><name name-style="western"><surname>Mehnert-Theuerkauf</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Course of self-reported dysphagia, voice impairment and pain in head and neck cancer survivors</article-title>. <source>Biol (Basel)</source>. (<year>2021</year>) <volume>10</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3390/biology10020144</pub-id><pub-id pub-id-type="pmcid">PMC7918686</pub-id><pub-id pub-id-type="pmid">33670412</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wichmann</surname><given-names>G</given-names></name><name name-style="western"><surname>Herchenhahn</surname><given-names>C</given-names></name><name name-style="western"><surname>Boehm</surname><given-names>A</given-names></name><name name-style="western"><surname>Mozet</surname><given-names>C</given-names></name><name name-style="western"><surname>Hofer</surname><given-names>M</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>HLA traits linked to development of head and neck squamous cell carcinoma affect the progression-free survival of patients</article-title>. <source>Oral Oncol</source>. (<year>2017</year>) <volume>69</volume>:<page-range>115&#8211;27</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.oraloncology.2017.04.017</pub-id><pub-id pub-id-type="pmid">28559015</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wichmann</surname><given-names>G</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Herchenhahn</surname><given-names>C</given-names></name><name name-style="western"><surname>Kolb</surname><given-names>M</given-names></name><name name-style="western"><surname>Hofer</surname><given-names>M</given-names></name><name name-style="western"><surname>Wiegand</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Development of a human leukocyte antigen score to predict progression-free survival in head and neck squamous cell carcinoma patients</article-title>. <source>Front Oncol</source>. (<year>2018</year>) <volume>8</volume>:<elocation-id>168</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fonc.2018.00168</pub-id><pub-id pub-id-type="pmid">29868484</pub-id><pub-id pub-id-type="pmcid">PMC5966661</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiegand</surname><given-names>S</given-names></name><name name-style="western"><surname>Wichmann</surname><given-names>G</given-names></name><name name-style="western"><surname>Dietz</surname><given-names>A</given-names></name></person-group>. <article-title>Perspectives of induction with chemo and/or immune check point inhibition in head and neck organ preservation treatment</article-title>. <source>Front Oncol</source>. (<year>2019</year>) <volume>9</volume>:<elocation-id>191</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fonc.2019.00191</pub-id><pub-id pub-id-type="pmid">30972299</pub-id><pub-id pub-id-type="pmcid">PMC6443982</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattavelli</surname><given-names>D</given-names></name><name name-style="western"><surname>Wichmann</surname><given-names>G</given-names></name><name name-style="western"><surname>Smussi</surname><given-names>D</given-names></name><name name-style="western"><surname>Paderno</surname><given-names>A</given-names></name><name name-style="western"><surname>Plana</surname><given-names>MS</given-names></name><name name-style="western"><surname>Mesia</surname><given-names>RN</given-names></name><etal/></person-group>. <article-title>Is precision medicine the solution to improve organ preservation in laryngeal/hypopharyngeal cancer? A position paper by the Preserve Research Group</article-title>. <source>Front Oncol</source>. (<year>2024</year>) <volume>14</volume>:<elocation-id>1433333</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fonc.2024.1433333</pub-id><pub-id pub-id-type="pmid">39165689</pub-id><pub-id pub-id-type="pmcid">PMC11333336</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>